Esophageal Achalasia

More than 300 million people worldwide, including one in every 10 Americans, are living with a rare disease, yet these individuals and their families are often left isolated and without answers.

In this edition, achalasia is associated with higher esophageal cancer risk; FDA rejects bulevirtide for hepatitis D and liver disease; real-world data on colonoscopy prep and more.

CHARLOTTE, N.C. — Achalasia was associated with an increased risk for esophageal cancer among a cohort of veterans, suggesting the need for increased endoscopic surveillance, according to a presenter at the ACG Annual Scientific Meeting.

The epidemiologic and economic burden of esophageal achalasia appears higher than previously reported, according to study results.

Healio Gastroenterology presents the following reports on the most recent research on the esophagus and GERD.

Long-term data from the GEMINI trial showed that Entyvio maintained its favorable safety profile in patients with inflammatory bowel disease over 8 years. It was the top story in gastroenterology last week.

The American College of Gastroenterology released clinical guidelines to diagnose and treat patients with achalasia.

Peroral endoscopic myotomy is highly safe and effective for at least 1 year for the treatment of achalasia and outperformed previous efficacy estimates, according to study results.

Using either posterior or anterior myotomy during peroral endoscopic myotomy can provide clinical success in the treatment of achalasia, according to study results.